Lyell Immunopharma Inc - LYEL Net earnings per share for the last four quarters

Official company branding of Lyell Immunopharma Inc (LYEL)

Lyell Immunopharma (LYEL) is developing a unique T-cell therapy environment. This chart illustrating the asset's market value on GURU.Markets confirms the effectiveness of this ecosystem, where the metric value stands at 50.40. The R&D center is intensively creating methods to combat solid tumors while preparing reports on new platforms. Meanwhile, operational processes and drug manufacturing have been delegated to external partners to optimize resources.

Lyell Immunopharma, Inc. (LYEL) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

LYEL (Lyell Immunopharma, Inc.): analytical breakdowns and indicator data

Initial company analysis:LYEL, Lyell Immunopharma Inc
Mass-produced product of lyell.com

This indicator measures the rate of capital accumulation under tight monetary policy, revealing hidden business stagnation. By analyzing the annual growth rate of earnings per share (ttm) on the GURU.Markets platform, an investor can track net income dynamics over 12 months relative to the previous year. The metric is calculated as the percentage change in EPS, reflecting the efficiency of profit scaling. For Lyell Immunopharma (LYEL), this trend depends critically on the success of T-cell therapy and patient survival rates in the treatment of solid tumors.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months